Literature DB >> 9217810

Immunohistochemical analysis of the skin in junctional epidermolysis bullosa using laminin 5 chain specific antibodies is of limited value in predicting the underlying gene mutation.

J R McMillan1, J A McGrath, L Pulkkinen, A Kon, R E Burgeson, J P Ortonne, G Meneguzzi, J Uitto, R A Eady.   

Abstract

The anchoring filament protein laminin 5 is composed of three polypeptide chains (alpha 3, beta 3 and gamma 2) each encoded by separate genes (LAMA3, LAMB3 and LAMC2, respectively). Mutations in any of these three genes may give rise to the autosomal recessive blistering skin disease, junctional epidermolysis bullosa. At present, there is no easy way of predicting which of these three genes might harbour the pathogenetic laminin 5 mutations in a case of junctional epidermolysis bullosa. In this study, we assessed whether immunohistochemistry might be helpful in this regard. We performed immunohistochemical labelling of the dermal-epidermal junction using alpha 3, beta 3 and gamma 2 chain-specific antibodies in 11 patients with junctional epidermolysis bullosa, in whom the laminin 5 mutations had been previously delineated. Although, labelling for the laminin 5 chain bearing the mutations was attenuated or undetectable in all cases, a complete absence of labelling or a reduction in the staining intensity for the other two chains was also seen in all cases. The results showed that immunohistochemical labelling of the dermal-epidermal junction using alpha 3, beta 3 and gamma 2 chain-specific antibodies is not a specific indicator for which of the laminin 5 chain genes contains the pathogenetic mutations, and is therefore unreliable in screening for individual laminin 5 gene mutations in cases of junctional epidermolysis bullosa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9217810

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

1.  Novel and recurrent mutations in the laminin-5 genes causing lethal junctional epidermolysis bullosa: molecular basis and clinical course of Herlitz disease.

Authors:  Christiane Mühle; Qiu-Jie Jiang; Alexandra Charlesworth; Leena Bruckner-Tuderman; Guerrino Meneguzzi; Holm Schneider
Journal:  Hum Genet       Date:  2004-11-05       Impact factor: 4.132

Review 2.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

3.  Laminins in normal, keratoconus, bullous keratopathy and scarred human corneas.

Authors:  Berit Byström; Ismo Virtanen; Patricia Rousselle; Kaoru Miyazaki; Christina Lindén; Fatima Pedrosa Domellöf
Journal:  Histochem Cell Biol       Date:  2007-05-11       Impact factor: 2.531

4.  Complexity of Transcriptional and Translational Interference of Laminin-332 Subunits in Junctional Epidermolysis Bullosa with LAMB3 Mutations.

Authors:  Ping-Chen Hou; Ken Natsuga; Wei-Ting Tu; Hsin-Yu Huang; Brandon Chen; Liang-Yu Chen; Wan-Rung Chen; Yi-Kai Hong; Yen-An Tang; Julia Yu-Yun Lee; Peng-Chieh Chen; H Sunny Sun; John A McGrath; Chao-Kai Hsu
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

5.  Extent of laminin-5 assembly and secretion effect junctional epidermolysis bullosa phenotype.

Authors:  C Matsui; P Pereira; C K Wang; C F Nelson; T Kutzkey; C Lanigan; D Woodley; M Morohashi; E A Welsh; W K Hoeffler
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

6.  Targeted next-generation sequencing identifies a novel mutation of LAMB3 in a Chinese neonatal patient presented with junctional epidermolysis bullosa.

Authors:  Hairong Wang; Yun Yang; Jieqiong Zhou; Jiangxia Cao; Xuelian He; Long Li; Shuyang Gao; Bing Mao; Ping Tian; Aifen Zhou
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa.

Authors:  Laura De Rosa; Sonia Carulli; Fabienne Cocchiarella; Daniela Quaglino; Elena Enzo; Eleonora Franchini; Alberto Giannetti; Giorgio De Santis; Alessandra Recchia; Graziella Pellegrini; Michele De Luca
Journal:  Stem Cell Reports       Date:  2013-12-26       Impact factor: 7.765

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.